A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1869-1877

  Schneider, Joachim ^a   Bitterlich, Norman ^b   Kotschy Lang, Nicola ^c   Raab, Wolfgang ^d   Woitowitz, Hans Joachim ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Medizin und Service GmbH   (Germany)

^c Berufsgenossenschaftliche Klinik fur Berufskrankheiten Falkenstein   (Germany)

^d Berufsgenossenschaftliche Klinik für Berufskrankheiten   (Germany)

Author keywords

Asbestosis; Fuzzy classifier; Lung cancer; Predictive value; Tumour markers

Indexed keywords

C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT;

ADULT; AGED; ASBESTOSIS; CANCER RISK; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FUZZY SYSTEM; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ANTIGENS, NEOPLASM; ASBESTOSIS; C-REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FUZZY LOGIC; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; SENSITIVITY AND SPECIFICITY; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 34250785537     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Butz M: Beruflich verursachte Krebserkrankungen. Eine Darstellung des Berufskrankheiten-Geschehens in Deutschland. Schriftenreihe des Hauptverbandes der gewerblichen Berufsgenossenschaften, St. Augustin, Germany, 1-72, 2005.
2. Keller T, Bitterlich N, Hilfenhaus S, Bigl H, Löser T and Leonhardt P: Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profiles. J Cancer Res Clin Oncol 124: 565-574, 1998.
3. Lamerz R, Hasholzner U and Stieber P: Immunologische Diagnostik und Tumormarker. In: Manual: Tumoren der Lunge und des Mediastinums. Schalhorn A (ed.). Zuckschwerdt Verlag München, pp. 20-25, 2000.
4. Yang HB, Hsu PI, Lee JC, Chan CH, Lin XZ and Chow NH: Adenoma-carcinoma sequence: a reappraisal with immunohistochemical expression of ferritin. J Surg Oncol 60: 35-40, 1995.
5. Sobin LH and Wittekind C: TNM Classification of Malignant Tumours. 5th Edition. John Wiley & Sons, New York, 1997.
6. Mountain CF. Revisions in the international system for staging lung cancer. Chest 111: 1710-1717, 1997.
7. Parker JE: Radiological criteria: The use of chest imaging techniques in asbestos-related diseases. In: Proceedings of an International Expert Meeting on Asbestos, Asbestosis and Cancer. People and Work. Finish Institute of Occupational Health, Helsinki, Finland, Research reports 14: 28-40, 1997.
8. Schneider J, Bitterlich N, Velcovsky HG, Morr H, Katz N and Eigenbrodt E: Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol 7: 145-151, 2002.
9. Kraus T and Raithel HJ: Frühdiagnostik asbeststaubverursachter Erkrankungen. Schriftenreihe des Hauptverbandes der gewerblichen Berufsgenossenschaften, Sankt Augustin, 1998.
10. Raithel HJ and Lehnert G: Aussagemöglichkeiten moderner computertomographischer Untersuchungsverfahren bei der Diagnose berufsbedingter Staublungenerkrankungen. Arbeitsmed Sozialmed Präventivmed 25: 144-150, 1990.
11. Vehmas T, Kivisaari L, Zitting A, Mattson K, Nordman H and Huuskonen M: Computed tomography (CT) and high resolution CT for the early diagnosis of lung and pleural disease in workers exposed to asbestos: Finnish experiences. In: Proceedings of an International Expert Meeting on New Advances in Radiology and Screening of Asbestos-related Diseases. Helsinki, Finnish Inst, of Occupational Health. People and Work Research Reports 36: 53-56, 2000.
12. Marek W, Krampe S, Dickgreber NJ, Nielsen L, Muti A, Khanavkar B, Müller KM, Atay Z, Topalidis T and Nakhosteen JA: Automatisierte quantitative Image-Zytometrie bronchialer Spülungen bei Verdacht auf ein Bronchialkarzinom: Vergleich mit Zytologie, Histologie und Enddiagnose. AtemwLungenkrkh 24: 316-319, 1998.
13. Böcking A, Biesterfeld S, Chatelain R, Gien-Gerlach G and Esser E: Diagnosis of bronchial carcinoma on sections of paraffin-embedded sputum. Sensitivity and specificity of an alternative to routine cytology. Acta Cytol 36: 37-47, 1992.
14. Schiller JH: Current standards of care in small cell and non-small cell lung cancer. Oncology 61: 3-13, 2001.
15. Schneider J: Tumor markers in detection of lung cancer. Advances Clin Chem 42: 1-41, 2006.
16. Schneider J, Velcovsky HG, Morr H, Katz N, Neu K and Eigenbrodt E: Comparison of the tumor markers Tumor M2-PK, CEA, CYFRA-21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 20: 5053-5058, 2000.
17. Molina R, Agusti C, Mane JM, Filella X, Jo J, Joseph J, Gimenez N, Estape J and Ballesta AM: CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 9: 96-101, 1994.
18. Ebert W, Hoppe M, Muley T and Drings P: Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA-TP, CEA, and NSE. Anticancer Res 17: 2875-2878, 1997.
19. Stieber P, Dienemann H, Hasholzner U, Müller C, Poley S, Hofmann K and Fateh-Moghadam A: Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide specific antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur J Clin Chem Clin Biochem 31: 689-694, 1993.
20. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Vinolas N, Marquez A, Barreiro E, Borras J and Viladiu P: Tumor marker (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 24: 209-218, 2003.
21. Plebani M, Basso D, Navaglia F, De-Paoli M, Tommasini A and Cipriani A: Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 72: 170-173, 1995.
22. Seemann MD, Beinert T, Furst H and Fink U: An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Lung Cancer 26: 149-155, 1999.
23. Giovanella L, Ceriani L, Bandera M, Rimoldi R, Beghe B and Roncari G: Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21-1) immunoradiometric assay in non small cell lung cancer evaluation. Q J Nucl Med 39: 285-289, 1995.
24. Moro D, Villemain D, Vuillez JP, Delord CA and Brambilla C: CEA, CYFRA 21-1 and SCC in non-small cell lung cancer. Lung Cancer 13: 169-176, 1995.
25. Koga H, Eguchi K, Shinkai T, Tamura T, Ohe Y, Oshita F, Saijo N, Kondo H, Oki K and Okura H: Preliminary evaluation of the new tumour marker CYFRA 21-1 in lung cancer patients. Jpn J Clin Oncol 24: 263-268, 1996.
26. Lombardi C, Tassi GF, Pizzicolo G and Donato F: Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis. Chest 97: 639-644, 1990.
27. Gail MH, Muenz L, Mc Intire KR, Radovich B, Braunstein G, Brown PR, Deftos L, Dnistrian A, Dunsmore M and Elashoff R: Multiple markers for lung cancer diagnosis: validation of models for advanced lung cancer. J Natl Cancer Inst 76: 805-816, 1986.
28. Gail MH, Muenz L, Mc Intire, Radovich B, Braunstein G, Brown PR, Deftos L, Dnistrian A, Dunsmore M, Elashoff R, Geller N, Go VLW, Hirji K, Klauber MR, Pee D, Petroni G, Schwartz M and Wolfsen AR: Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer. J Nat Cancer Inst 80: 97-101, 1988.
29. Schneider J, Bitterlich N and Schulze G: Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the Tumor M2-PK. Anticancer Res 25: 1507-1516, 2005.
30. Schneider J, Peltri G, Bitterlich N, Philipp M, Velcovsky HG, Morr H, Katz N and Eigenbrodt E: Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small cell lung cancer patients. Clin Exp Med 2: 185-191, 2003.
31. Henschke CI, McCauley DI, Yankelvitz DF, Naidich DP, McGuiness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK and Smith JP: Early lung cancer action project: overall design and findings from baseline screening. Lancet 354: 99-105, 1999.